RxDoctor Payments Data

Bala Prabakaran, MD

Cardiovascular Disease · Fort Myers, FLNPI 1588692230

Payments from drug & device makers

$2,713in general payments, 2019–2025

Across 196 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$948
  • Novartis$284
  • Boehringer Ingelheim$253
  • Philips North America LLC$244
  • Amgen$212
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$204
  • plus $569 from 12 others

What the payments were for

  • Food & beverage$2,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,713 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$114,523
Medicare patients
575
Services billed
1,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban362$403,428
XareltoRivaroxaban90$105,326
EntrestoSacubitril/Valsartan91$102,039
MultaqDronedarone Hcl60$84,233
JardianceEmpagliflozin20$26,620
Repatha SureclickEvolocumab22$17,993
Digoxin112$3,254
Metoprolol Succinate241$3,063
Fenofibrate13$2,049
Metoprolol Tartrate282$1,766
Ranolazine ErRanolazine18$1,758
Bisoprolol Fumarate74$1,640
Amlodipine Besylate207$1,630
Pravastatin Sodium55$1,337
SotalolSotalol Hcl50$1,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$127$403,428362 claims
Johnson & JohnsonXarelto$948$105,32690 claims
NovartisEntresto$284$102,03991 claims
Sanofi-aventis U.S. LLCMultaq$65$84,23360 claims
Boehringer IngelheimJardiance$253$26,62020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →